go - International health experts say Canada is no longer measles-free because of ongoing outbreaks, as childhood vaccination rates fall and the highly contagious virus spreads across North and South America
#healthcare #publichealth #governmentpolicy
Monday, November 10, 2025, 11:22 pm / permalink 15856 / 4 stories in 4 months
fiercehealthcare - The action, announced Monday, follows a comprehensive review of scientific literature by an expert panel at the agency in July, as well as a public comment period, officials said. Pharmas are expected to update and reprint their product labeling to remove…
#healthcare #pharmaceuticals #publichealth #governmentpolicy
Monday, November 10, 2025, 5:24 pm / permalink 15854 / 5 stories in 4 months
Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months
Amanda Holpuch / nytimes - Health agencies asked caregivers to stop using two batches of ByHeart Whole Nutrition Infant Formula after they found an increase in cases of infant botulism.
Monday, November 10, 2025, 12:21 am / permalink 15822 / 2 stories in 4 months
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours
AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: